Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Thera (NQ: AXSM )

97.99 -0.20 (-0.20%)
Streaming Delayed Price Updated: 11:33 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Thera

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
19 20 Next >
Axsome Therapeutics' Sunosi Improves Cognitive Function In Patients With Sleep Disorder
Via Benzinga
Axsome Therapeutics Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea
From Axsome Therapeutics, Inc.
Via GlobeNewswire
8 Analysts Have This to Say About Axsome Therapeutics
Analysts have provided the following ratings for Axsome Therapeutics (NASDAQ:AXSM) within the last quarter: 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Mizuho Bolsters Price Target By 55% On This Migraine Stock
Via Benzinga
Analyst Ratings for Axsome Therapeutics
Within the last quarter, Axsome Therapeutics (NASDAQ:AXSM) has observed the following analyst ratings: 
Via Benzinga
Expert Ratings for Axsome Therapeutics
Within the last quarter, Axsome Therapeutics (NASDAQ:AXSM) has observed the following analyst ratings: 
Via Benzinga
Boxed Warnings May Not Hinder This Depression Drug's Broad Market Penetration, Analyst Says
Via Benzinga
Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
These Were the Five Best And Worst Performing Mid-Cap Stocks In August 2022
We have used the August return data from finviz.com to come up with the five best and worst performing mid-cap stocks in August 2022. 
Via Talk Markets
7 Top-Rated Biotech Stocks to Buy for Q4
A new White House program makes these seven names some outstanding biotech stocks to buy for the fourth quarter. 
Via InvestorPlace
Biotech Stocks Stand to Benefit as Biden Announces Support for Industry
President Biden has announced a new initiative to help U.S. biotech producers grow. Here's what this news means for biotech stocks. 
Via InvestorPlace
Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Axsome Therapeutics Commences Late-Stage Migraine Study
Axsome Therapeutics (NASDAQ: AXSM) has enrolled the first patient in the EMERGE trial of its lead candidate AXS-07 for the acute treatment of migraine. 
Via Benzinga
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. 
Via Benzinga
HC Wainwright Boosts Price Target On This Stock By 167%, Plus B of A Securities Predicts $40 For This Online Travel Stock
HC Wainwright & Co. raised the price target for Rockwell Medical, Inc. (NASDAQ: RMTI) from $3 to $8. Rockwell Medical shares rose 0.7% to close at $1.42 on Monday. 
Via Benzinga
$1000 Invested In Axsome Therapeutics 5 Years Ago Would Be Worth This Much Today
Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 5 years by 57.38% on an annualized basis producing an average annual return of 67.54%. Currently, Axsome Therapeutics has a... 
Via Benzinga
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others
These names are benefitting from M&A, clinical data and promising regulatory actions. 
Via Investor's Business Daily
AXSOME THERAPEUTICS INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Axsome Therapeutics, Inc. - AXSM
From Kahn Swick & Foti, LLC
Via Business Wire
AMC Entertainment Price Target Cut By This Analyst, Plus DA Davidson Predicts $318 For Estée Lauder
DA Davidson cut the price target for The Estée Lauder Companies Inc. (NYSE: EL) from $342 to $318. Estée Lauder shares fell 0.4% to $264.29 in pre-market trading. 
Via Benzinga
Netflix Price Target Cut By This Analyst, Plus Morgan Stanley Predicts $403 For McKesson
UBS cut the price target for Coupa Software Incorporated (NASDAQ: COUP) from $84 to $76. Coupa Software shares fell 4.9% to $64.44 in pre-market trading. 
Via Benzinga
Stocks That Made New Highs On Friday, Aug. 19
On Friday, in spite of the stock market being down, there were several stocks that actually made new highs. 
Via Talk Markets
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
S&P 500 Down More Than 1%; Bed Bath & Beyond Shares Plummet
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping over 250 points on Friday. 
Via Benzinga
Why GigaCloud Technology Jumped 206%; Here Are 79 Biggest Movers From Yesterday
Gainers GigaCloud Technology Inc (NASDAQ: GCT) shares jumped 206% to close at $48.01 on Friday on continued volatility following the company's IPO on Thursday. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
  
Via Benzinga
Axsome Therapeutics Rockets After Winning FDA Approval For A New Depression Drug
Axsome's drug targets a neurotransmitter believed to play a role in depression. 
Via Investor's Business Daily
Why Bed Bath & Beyond Is Trading Lower By Over 40%, Here Are 55 Stocks Moving In Friday's Mid-Day Session
Gainers GigaCloud Technology Inc (NASDAQ: GCT) shares jumped 145% to $38.45 on continued volatility following the company's IPO on Thursday. 
Via Benzinga
How Is The Market Feeling About Axsome Therapeutics?
Axsome Therapeutics's (NASDAQ:AXSM) short percent of float has fallen 3.86% since its last report. The company recently reported that it has 5.75 million shares sold short, which... 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
19 20 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.